
Pharmacally
Zidesamtinib
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Zidesamtinib
Clinical TrialsZidesamtinib Shows 94% Response Rate in ROS1-Positive NSCLCGSK’s zidesamtinib produced a 94% objective response rate in TKI-naïve patients with ROS1-positive NSCLC, with 90% progression-free at 12 months.Fact-Checked
Clinical TrialsNuvalent’s Zidesamtinib Demonstrates Strong Activity in Pretreated ROS1+ NSCLCNew data from the ARROS-1 trial show that zidesamtinib demonstrated clinically meaningful responses, including intracranial activity, in heavily pretreated ROS1-positive NSCLC, supporting its potential role after prior ROS1-targeted…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.